Associations between demographic, disease related, and treatment pathway related variables and health related quality of life in primary care patients with coronary heart disease by Lena Kramer et al.
Kramer et al. Health and Quality of Life Outcomes 2012, 10:78
http://www.hqlo.com/content/10/1/78RESEARCH Open AccessAssociations between demographic, disease
related, and treatment pathway related variables
and health related quality of life in primary care
patients with coronary heart disease
Lena Kramer*, Oliver Hirsch, Kathrin Schlöβler, Susanne Träger, Erika Baum and Norbert Donner-BanzhoffAbstract
Background: Coronory heart disease (CHD) is a common medical problem worldwide that demands shared care of
general practitioners and cardiologists for concerned patients. In order to improve the cooperation between both
medical specialists and to optimize evidence-based care, a treatment pathway for patients with CHD was developed
and evaluated in a feasibility study according to the recommendation for the development and evaluation of complex
interventions of the British Medical Research Council (MRC). In the context of this feasibility study the objective of the
present research was to investigate the contributions of different disease related (e.g. prior myocardial infarction),
pathway related (e.g. basic medication) and demographic variables on patients` perceived health related quality of life
(HRQoL) as a relevant and widely used outcome measure in cardiac populations.
Methods: Data assessing demographic, disease and pathway related variables of CHD patients included in the study
were collected in a quasi-experimental design with three study arms (pathway developers, users, control group) via
case record forms and questionnaires at baseline and after 6 and 12 (intervention groups), and 9 months (control
group), respectively after the initial implementation on GP level. Additionally, at the same measuring points the CHD
patients participating in the study were interviewed by phone regarding their perceived HRQoL, measured with the
EuroQol EQ-5D as an index-based health questionnaire. Due to the hierarchical structure of the data, we performed
cross-sectional and longitudinal linear mixed models to investigate the impact of disease related, pathway related and
demographic variables on patients` perceived HRQoL.
Results: Of 334 initially recruited patients with CHD, a total of 290 were included in our analysis. This was an average
13.2% dropout rate from baseline assessment to the 12-month follow-up. At all assessment points, patients` HRQoL was
associated with a variety of sociodemographic variables (e.g. gender, employment, education) in each study group, but
there was no association with pathway related variables. In both cross-sectional and longitudinal analyses highest HRQoL
values in patients were reported in the physician group that had developed the pathway. In the longitudinal analyses
there were no significant changes in the reported HRQoL values of the three groups over time.
Conclusions: The found associations between sociodemographic variables and the perceived HRQoL of patients with
CHD are in line with other research. As there are no associations of HRQoL with pathway related variables like the basic
medication, possible weaknesses in the study design or the choice of outcome have to be considered before planning
and conducting an evaluation study according to the MRC recommendations. Additionally, as patients in the developer
group reported the highest HRQoL values over time, a higher commitment of the GPs in the developer group can be
assumed and should be considered in further research.
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Coronary heart disease (CHD) is worldwide the leading
cause for morbidity and mortality in adults [1], although
in high income countries the mortality of patients with
CHD has decreased in recent years [2,3]. In Germany,
prevalence rates in the general population are 6.5%
(women) to 9.1% (men) [4]. For affected patients CHD
has often significant consequences (e.g. limited function-
ality, regular medication and monitoring visits) for their
entire life. Beside conventional somatic measures like
morbidity and mortality, health related quality of life
(HRQoL) has become more and more a relevant health
outcome to assess the effects of chronic illness on
patient’s daily life. In contrast to patients` satisfaction,
another widely used outcome measure that was shown
in several European studies to be not an adequate out-
come due to ceiling effects [5,6], HRQoL is a suitable
endpoint in cardiac populations [7,8], also in terms of
long-term prognosis [9]. HRQoL is understood as a
multidimensional concept representing patient’s subject-
ive perception of his physical, psychological and social
health status as well as his general well-being [10]. A
common instrument to assess patients HRQoL is the
Euroqol EQ-5D [11,12], a generic index-based health
questionnaire, which was validated across different dis-
eases, populations and countries [11-14]. In the context
of cardiovascular disorders a review by Dyer et al.
showed evidence for validity and reliability of the EQ-5D
in patients with cardiovascular disease [15]. The EQ-5D
index correlates negatively with the severity of cardiac
disease. Other factors as age or physical ability (mea-
sured in Treadmill exercise time) were shown to have a
smaller influence on HRQoL whereas gender had a
strong influence [16]. Even after adjustment for depres-
sive symptoms, social support and baseline EQ-5D
values, the measured HRQoL of women with CHD was
rated lower [17].
To guarantee appropriate care for patients with CHD in
primary care, an effective cooperation of general practi-
tioner (GP) and cardiologist with a focus on the GPs´
gatekeeper role is essential. This is of special interest in
countries with a social insurance based health care system
(SIS; also called “Bismarck” type health care system). In
contrast to countries with a national health care system
(NHS; also called “Beveridge” type health care system),
which is characterized by a strong governmental influence
and funding on taxation, SIS are less regulated by institu-
tional standards and funded by non-profit insurance
funds. Patients have quasi-universal access to care with
only a very limited gate-keeper role of the GP [18]. Thus,
competition between medical professionals in the ambula-
tory sector (primary and secondary care) hinders cooper-
ation. In this context the establishment of shared care
plans is – despite their need- difficult to achieve. Oneapproach to facilitate the adaption of shared care is the
provision of clinical pathways. Those are multidisciplinary,
locally translatable, and involve a stepwise procedure,
determined timeframes, and standardized care for a spe-
cific clinical problem [19]. In contrast to medical guide-
lines, which also aim for a standardized patient care,
treatment pathways are a more active and more specific
form of implementation with a strong bottom-up compo-
nent [20]. Although the implementation of treatment
pathways faces similar problems as the implementation of
guidelines [21,22], pathways are supposed to possess
higher implementation chances by adapting the guideline
recommendations to local conditions [23,24]. However,
the effect of local treatment pathways is controversial as
not always an implementation benefit by the local adapta-
tion was found [25]. Possible effects of the CHD pathway
might be an improvement in medication, more appropri-
ate visits, familiarity with the guideline and exchange be-
tween the providers. Due to these assumptions we
developed a treatment pathway for patients with CHD in
a SIS as most research was yet done in countries with a
NHS. As the pathway contained several interacting com-
ponents and can thus be considered as complex interven-
tion we followed the recommendations regarding the
development and evaluation of complex interventions,
proposed by the British Medical Research Council (MRC)
[26]. According to this iterative model the theory-based
development of the complex intervention is followed by
exploratory feasibility studies to detect, check and modify
potential limitations in the study design before potentially
planning and conducting a subsequent evaluation study to
assess the intervention’s effectiveness, if possible in a ran-
domized controlled trial (RCT). Within the context of this
feasibility study we aimed to investigate the impact of dif-
ferent disease related (e.g. prior myocardial infarction),
pathway related (e.g. basic medication) and demographic
components on patients` perceived HRQoL as one rele-
vant health outcome in CHD patients.
Methods
Development and description of the CHD pathway
The pathway development was performed in cooperation
with 14 GPs and 4 cardiologists of the Marburg region,
Germany, who were invited by the Department of General
Practice/Family Medicine at the University of Marburg.
We assumed that by realizing a bottom-up approach [20]
physicians` adherence to the recommendations of the
treatment pathway would be enhanced. By doing so it was
intended to coordinate prescription of drugs and schedul-
ing regular visits with the GP and the cardiologist. The de-
velopment of the pathway was based on current regional
[27] and national care guidelines [28]. Within small work-
ing groups moderated by members of our department,
plans for monitoring visits (examinations, referral
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mentation forms were developed and brought to a consen-
sus with all participants. To support the implementation
of the pathway and to improve the communication and
cooperation between GPs and cardiologists in daily prac-
tice, we provided the physicians with both a laminated
pocket version of the pathway guidelines covering drugs
and monitoring visits, and patient treatment logs to list
medication and monitoring visits for every patient. An
overview of the pocket version of the pathway is given in
Additional file 1: Table S1.
Study design
The study was conducted as a quasi-experimental trial
with three study arms. We used GPs as the unit of classifi-
cation. All practices of the intervention groups (A: path-
way developers, B: users) were located in the Marburg
region, Germany, whereas the practices of the control
group (C) were situated in a neighbouring town. The par-
ticipating physicians were recruited from the regional
physician network of the Department of General Practice/
Family Medicine. GPs and cardiologists in both interven-
tion groups received the pathway material. The control
group did not receive any pathway material and treated
their patients with CHD as usual. GPs got monetary com-
pensation for the recruitment of patients and – if applic-
able – for their participation in the development of the
treatment pathway. All practices were visited by a study
nurse to give an introduction in the study flow and docu-
ments. Beside the quantitative evaluation of the CHD
pathway we conducted semi-structured interviews with
the participating GPs to gain further insight into GPs
opinion regarding the pathway [29]. An overview of the
intended study design is given in Figure 1.Figure 1 Intended study design.At baseline, data collection for the CHD patients
included in the study was performed by the participating
GPs in case record forms which contained information
about medical investigations, laboratory data like lipid
values, liver enzymes and kidney values, medication, refer-
rals to cardiologists, and hospitalizations. In both inter-
vention groups, follow-up assessments with the same case
record forms were done at 6 and 12 months. We did not
expect remarkable changes in the control group. There-
fore, we conducted one follow-up assessment after
9 months. In our analyses we compared the 9 months
follow-up data of the control group with both follow-up
data of the intervention groups at 6 and 12 months.
Additionally, at the same measuring points patients
were asked with standardized questionnaires about their
HRQoL and their treatment satisfaction. While at base-
line the assessment was paper-pencil based, the follow-
up interviews were conducted via phone by independent
interviewers. Follow-up intervals of case record form
and patients` assessment were identical. Physicians and
patients were informed in written form about the study
and gave their consent to study participation. Ethic ap-
proval for the study was obtained from the Ethics Com-
mittee of the Faculty of Medicine at Philipps University
Marburg, Germany.
Data collection
The demographic and disease related variables we
included in our analyses comprised patients` age, gender,
living with partner, education level, employment, prior
myocardial infarction and prior bypass or stent. Regard-
ing the pathway we aimed to investigate the impact of
monitoring visits and relevant drugs on patients`
HRQoL. As the data for monitoring visits showed no
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variable from our analyses and focussed on the basic
evidence-based medication recommended by the CHD
pathway.
Due to the complexity of recommendations regarding
drug management, we concentrated on the effects of
basic evidence-based medication for CHD on HRQoL.
The medication with cholesterol-lowering drugs like sta-
tins and antiplatelet agents (e.g. acetylsalicylic acid or
clopidogrel) is considered as basic evidence-based ther-
apy in patients with CHD and could be demonstrated as
being effective in a variety of studies [30-37]. Based on
the prescription of basic evidence-based medication
patients were classified as “basic therapy completely
achieved” when cholesterol-lowering drugs (statins,
fibrates) and antiplatelet agents (ASA, clopidogrel) or al-
ternatively anticoagulant agents (phenprocoumon/war-
farin or heparin) were given. If patients received only
one drug class they were classified as “cholesterol-
lowering drugs achieved” or “antiplatelet/anticoagulant
agents achieved”. In spite of their different indication we
did not distinguish between antiplatelet and anticoagu-
lant agents as basic evidence-based medication. While
anticoagulant agents are recommended for stroke pre-
vention in patients with tachyarrhythmia absoluta and
atrial fibrillation or for thrombosis prophylaxis, antipla-
telet agents are essential drugs in the treatment of CHD.
For patients having an indication for an anticoagulative
therapy a combination with antiplatelet drugs is not
recommended [30,31]. This recommendation is not valid
in comorbid patients having had a myocardial event (in-
farction, stent implantation) in the past 12 months. In
line with the pathway in theses cases a combined medi-
cation is indicated. As statins have adverse effects, which
might impact the compliance of patients, we also
included fibrates as cholesterol-lowering drugs as a basic
evidence-based medication.
The primary endpoint of the study was patients` per-
ceived health related quality of life, which was assessed
by the Euroqol EQ-5D [11,12]. The EQ-5D describes
present-day health status on five dimensions: mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. Each dimension is represented by one ques-
tion with three severity levels (no problems, some or
moderate problems and extreme problems). Psycho-
metric qualities are comparable to those of similar
instruments like the Short-Form 36 Health Survey
Questionnaire (SF-36)[38,39]. The five health dimension
items can be used to generate a single index value by ap-
plying societal preference weights. These preference
weights and an algorithm for calculating the index are
available for different countries [40]. According to the
recommendations for quality of life analyses in clinical
studies we used the preference weights of a Europeansample [41,42]. The index ranges from 1 (full health) to 0
(dead) with some states being worse than dead (< 0).
Study sample
According to our study design we asked 18 GPs (6 path-
way developers, 6 users, 6 control physicians) to partici-
pate in our study and to recruit consecutively patients
with CHD. Inclusion criterion was the existence of an is-
chemic heart disease (I20-I25 of the ICD-10). Patients
with currently treated carcinoma, COPD stage III-IV or
renal insufficiency stage IV-V were excluded. Sample
size calculation was performed with the programme
“Sampsize Version 1.0.2” by the Health Services Re-
search Unit of the University of Aberdeen (http://www.
abdn.ac.uk/hsru/research/delivery/behaviour/methodo-
logical-research). Regarding the EQ-5D Index we aimed
to detect a minimum difference of 15 points with a
standard deviation of 25. The minimum sample size for
each of our intended 18 GPs at a significance level of
p = .05, 80% power, and an estimated intracluster correl-
ation coefficient of .10 would be 16 patients. An
intracluster correlation of .10 is a conservative estimate
[43].
Data analysis
Baseline characteristics of physicians were compared
using the Freeman-Halton extension of Fisher`s exact
test because of low numbers in our 2 × 3 tables [44]. The
Kruskal-Wallis test was used to examine absolute differ-
ences in age.
We analyzed baseline characteristics of patients to
identify possible selection bias in the three study arms
and performed detailed comparisons between study
dropouts and participants.
Cross-tab analyses with χ2-tests and standardized resi-
duals were performed using Cramer-V as an effect size.
A value of .40 or higher denotes a large effect [45,46].
The Kruskal-Wallis test was used to examine absolute
differences in age.
Due to the hierarchical structure of the data (patients
nested within physicians) we used cross-sectional and
longitudinal linear mixed models with restricted max-
imum likelihood (REML) estimation to measure associa-
tions between predictors and quality of life dependent
variables (EQ-5D Index) [47]. This approach is capable
of controlling for variations in patient and physician
characteristics. Intraclass correlation coefficients (ICC)
were calculated for each quality of life variable and as-
sessment point to indicate whether practices were het-
erogeneous regarding these variables. At an intraclass
coefficient of at least .05 a multilevel analysis should be
performed [48]. We considered a predictor to be signifi-
cant if the T statistic of the regression coefficient corre-
sponded to an alpha level of <.05. Tukey`s Least
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adjusted mean differences within significant categorical
predictors. Evidence-based medication, the interaction
between evidence-based medication and physician
group, patients` age, gender, living with partner, educa-
tion level, employment, prior myocardial infarction and
prior bypass or stent were entered as fixed effects. We
also tried to integrate them as random effects. Due to
the different follow-up assessments between control and
intervention groups we applied the last observation car-
ried forward (LOCF) method to impute the missing
measurements of the control group at 12 month follow-
up with their respective data at 9 month follow-up. Al-
though the use of LOCF has its critics due to its
increased potential for bias [49], we thought this ap-
proach to be plausible and appropriate as we did not ex-
pect change in the control group from the moment of
dropout onwards [50]. Patients in the control group had
a long history of medical treatment because of CHD and
the treatment regiment was not changed during the
study period. This has to be considered when interpret-
ing the results [51]. Statistical analysis was performed
with SPSS 19.0.Results
Sample characteristics
A total of 20 GPs (8 pathway developers, 6 users, 6 con-
trol physicians) participated in the study. Table 1 sum-
marizes the characteristics of the participating GPs.
During the recruitment period 415 patients with exist-
ing CHD had been invited to participate of whom 334
patients agreed. Of these, 290 patients could be included
in the final sample (Figure 2).
The number of patients recruited by each of the 20
GPs ranged between 9 and 24 (mean cluster size 17.1).Table 1 Sociodemographic characteristics of the GPs







N 8 6 6
Mean age (year) 50.8 52.8 51.3 .77
Gendera .06
female (%) 4 (50.0) 1 (16.7) 5 (83.3)
male (%) 4 (50.0) 5 (83.3) 1 (16.6)
Practice locationa .87
town (%) 4 (50.0) 3 (50.0) 4 (66.6)




single practice 3 (37.5) 2 (33.3) 4 (66.6)
group practice 5 (62.5) 4 (66.6) 2 (33.3.)As seen in Table 2 most of the participating patients
were male (68%), lived with a partner (72%), did not
work (80%) and had a mean age of 69 years. The major-
ity (64%) had an education level of 9 or less years,
reported prior myocardial infarction (53%) and prior
coronary intervention (79%).
There were no differences between the study arms in
sociodemographic and baseline characteristics except gen-
der and living with partner. Significantly more patients in
study arm A (developers) were male (χ2 = 12.09, df = 2,
p = .002, Cramer-V= .20) and living with a partner
(χ2 = 7.77, df = 2, p = .02, Cramer-V= .16), whereas in study
arm C (control) women not living with a partner were
overrepresented, compared to the other groups.
Dropout analysis
There was an average 13.2% dropout rate from baseline
assessment to the final follow-up assessment (n = 44).
The proportion in study arm B (users) was highest with
15.7% (13 out of 83 at baseline), in study arm C (control)
14.0% (15 out of 107) and in study arm A 11.1% (16 out
of 144 at baseline) (see Figure 2).
There were no differences between the final sample
and dropouts in sociodemographic and baseline charac-
teristics except living with partner (χ2 = 4.81, df = 1,
p = .03, Cramer-V= .12), employment (χ2 = 5.01, df = 1,
p = .03, Cramer-V= .12) and prior myocardial infarction
(χ2 = 5.85, df = 1, p = .02, Cramer-V= .13). Dropouts more
often lived without partner, did not have an employment
and had no myocardial infarction in the past compared
to the final sample. All effect sizes can be considered
small.
Cross sectional analyses
As Table 3 shows, ICCs are> .05, so that multilevel ana-
lyses are feasible.
Table 4 summarizes the results of the multilevel cross
sectional analyses for all assessment points. The integra-
tion of the predictors as random was not possible be-
cause the respective models did not converge.
At baseline there was no significant association be-
tween any of the predictors and the EQ-5D-Index except
for employment. Patients who were employed had a sig-
nificantly higher EQ-5D Index (81.76, standard error
3.49) than those who were not employed (72.55, stand-
ard error 1.84; p = .01).
At the first follow-up assessment patients in the devel-
oper group had a significantly higher EQ-5D Index
(77.39, standard error 2.66) than those in the control
group (67.66, standard error 2.88; p = .02). There was no
significant difference between the user group (70.37,
standard error 3.20) and these two groups. Male patients
(76.39, standard error 2.04) had a significantly higher
EQ-5D Index than females (67.23, standard error 2.67;
Figure 2 Patient flowchart.
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(77.35, standard error 3.17) had a significantly higher
EQ-5D Index than those with up to 9 or less years of
education (67.58, standard error 1.89; p = .004).
At the second follow-up assessment patients in the de-
veloper group had a significantly higher EQ-5D Index
(77.38, standard error 2.31) than those in the control
group (68.35, standard error 2.35) and in the user group
(66.45, standard error 2.83; p = .02 and p= .01, respect-
ively). Patients without a previous myocardial infarction
had a significantly higher EQ-5D Index (73.00, standard
error 2.13) than those who had had a prior myocardial
infarction (68.46, standard error 2.01; p = .04). Male
patients (73.67, standard error 1.85) had a significantly
higher EQ-5D Index than females (67.79, standard error
2.50; p = .02). Patients with 11 to 13 years of education
(74.50, standard error 2.98) had a significantly higher
EQ-5D Index than those with up to 9 years of education
(67.37, standard error 1.68; p = .03).Longitudinal analyses
Results of the longitudinal analyses are shown in Table 5.
The integration of the predictors as random was not
possible because the respective models did not converge.
As seen in Figure 3 the user and the control group
had different longitudinal characteristics in the EQ-5D
Index over time. At the first follow-up there was a rise
in the user group and a decline in the control group. Butat the second follow-up, both groups had the same
scores again.
Patients with a prior myocardial infarction had a larger
decline in the EQ-5D Index than those without myocar-
dial infarction. Women had a larger decline than men in
the EQ-5D Index from baseline to first follow-up. Those
with 11 to 13 years of education had a rise in the EQ-5D
Index from baseline to first follow-up and then a decline
while those with up to 9 years and those with 10 years
of education had a decline from baseline to first follow-
up which then leveled off.
Discussion
Main findings
The results of our cross-sectional analyses indicate that
at all assessment points, patients` HRQoL was asso-
ciated with a variety of sociodemographic variables and
study group membership whereas there was no associ-
ation with pathway related variables like the basic
evidence-based medication as one major recommenda-
tion of the CHD pathway.
The higher values at baseline in employed patients for
the EQ-5D Index are in line with the findings gained in
populations with other chronic diseases where employ-
ment led to higher HRQoL values [52-54]. The EQ-5D
Index values at the first and second follow-up rose for
patients in the developer group, men and patients with
higher education level. At the second follow-up also the
absence of a prior myocardial infarction had an impact
Table 3 Means and standard deviations (sd) of EQ-5D
index and their respective intraclass correlation
coefficients (ICC)
Group Index t0 Index t1 Index t2
Developers 80.59 (16.95) 78.12 (17.29) 77.82 (16.08)
Users 68.74 (20.71) 69.36 (21.04) 66.20 (18.70)
Control 69.94 (20.97) 66.45 (25.39) 66.45 (25.39)
ICC .129 .089 .100
Table 2 Sociodemographic and baseline characteristics of
the patientsa



















female (%) 27 (21.1) 27 (38.6) 38 (41.3)
male (%) 101 (78.9) 43 (61.4) 54 (58.7)
Living with partnerb .02
yes (%) 102 (79.7) 49 (71.0) 57 (62.6)
no (%) 26 (20.3) 20 (29.0) 34 (37.4)
Education level .25
9 or less years 85 (67.5) 45 (67.2) 55 (62.5)
10 years 22 (17.5) 6 (9.0) 18 (20.5)
11-13 years 19 (15.1) 16 (23.9) 15 (17.0)
Employment .13
yes (%) 30 (23.6) 11 (16.2) 12 (13.3)
no (%) 97 (76.4) 57 (83.8) 78 (86.7)
Prior myocardial infarction .46
yes (%) 67 (52.3) 42 (60.0) 45 (50.6)
no (%) 61 (47.7) 28 (40.0) 44 (49.4)
Prior bypass or stent .16
yes (%) 105 (82.0) 58 (84.1) 65 (73.0)
no (%) 23 (18.0) 11 (15.9) 24 (27.0)
a Numbers may not add up to 290 and percentages may not add up to 100 %
due to missing values and rounding.
b Significant difference between groups (α= .05).
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herent with other research as several studies in patients
with CHD showed a higher HRQoL for men [55,56]. The
reasons for these gender-related differences remain un-
clear. Possible explanations are that women with CHD areTable 4 Estimated multilevel regression coefficients for fixed
value of the T statistic for the predictors and the dependent
Index t0
group −4.58 (3.08) p = .14
medication −1.72 (3.47) p = .62
group*medication −0.14 (1.65) p = .93
myocardial infarction −3.17 (2.38) p = .19
bypass/stent 1.80 (3.04) p = .56
gender −2.77 (2.72) p = .31
age 0.18 (0.15) p = .21
partner −2.75 (2.71) p = .31
employment −9.21 (3.73) p = .01**
education 2.17 (1.51) p = .15
* p< .05; ** p< .01.older, have a higher burden of comorbid illnesses and are
more often widowed or living alone [16,55]. Also educa-
tion and the related socioeconomic status are well estab-
lished determinants for CHD as low education and
socioeconomic disadvantage are linked to a higher risk of
cardiovascular mortality and morbidity [57].
In the longitudinal analyses EQ-5D Index values declined
for women and patients with a prior myocardial infarction
over time whereas the gradient for education level showed
no linear development. Patients with a prior myocardial in-
farction can be categorized as having a more severe CHD.
In line with our results a review by Dyer and colleagues
showed decreased values of the EQ-5D index in patients
with severe heart disease [15]. As in our study, women re-
port significantly worse health status after myocardial in-
farction than men. Compared to both other study groups
patients of the developer group at all times had higher
values in the EQ-5D index. An explanation for the results
of the longitudinal analysis might be the shortness of inter-
vals between the assessment points, so that situational
influences could have affected patients` HRQoL ratings.
Higher HRQoL values of patients in the developer
group might be due to a higher commitment and dee-
pened preoccupation with the pathway recommenda-
tions of those physicians who participated in the
pathway development. Grimshaw and colleagues showed
in their study that the participation in developing an
innovation could enhance the compliance in physicianseffects, their standard errors (in parentheses), and p
variables at baseline, first and second follow-up
Index t1 Index t2
−6.21 (3.05) p = .05* −7.87 (2.98) p = .01**
−2.66 (3.71) p = .48 −5.50 (3.50) p = .12
0.92 (1.74) p = .60 2.10 (1.65) p = .21
−3.66 (2.57) p = .16 −5.20 (2.48) p = .04*
−0.93 (3.28) p = .78 1.27 (3.16) p = .69
−9.50 (2.95) p = .001** −6.45 (2.84) p = .02*
0.01 (0.16) p = .97 −0.10 (0.15) p = .53
−1.09 (2.93) p = .71 −0.86 (2.82) p = .76
−1.36 (4.02) p = .74 −1.69 (3.88) p = .66
4.56 (1.62) p = .005** 3.25 (1.57) p = .04*
Table 5 Estimated multilevel regression coefficients for
fixed effects, their standard errors (in parentheses), and
p values of the T statistic for the predictors and the
dependent variables in the longitudinal analyses
Index
group −5.02* (2.09) p = .03
time −1.34 (1.91) p = .48
group*time −0.08 (0.94) p = .94
medication −1.52 (0.85) p = .07
myocardial infarction −4.39** (1.42) p = .002
bypass/stent 0.15 (1.82) p = .94
gender −6.45** (1.62) p< .001
age −0.01 (0.09) p = .90
partner −1.09 (1.62) p = .50
employment −3.73 (2.23) p = .09
education 3.33** (0.91) p< .001
* p< .05; ** p< .01
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http://www.hqlo.com/content/10/1/78about 32%, whereas it was improved 22% in non-
developers [58]. The appreciation of the developer group
regarding their participation in the pathway develop-
ment could also been shown in our qualitative analysis,
where the GPs gave a positive evaluation of their partici-
pation and had a high identification with the pathway
content [29]. This appraisal of the pathway and its devel-
opment did not automatically lead to a behaviour change
according to the pathway recommendations as theFigure 3 Changes in the EQ-5D Index over the three assessment poinqualitative and quantitative data revealed. In the inter-
views the GPs reported to have already treated their
patients according to the pathway recommendations,
but by considering the results of basic drug prescription
no difference in prescription behaviour in the three
study arms became obvious. Despite these findings
patients of GPs who were involved in the development
of a complex intervention like the CHD pathway and
appreciated this participation showed higher EQ-5D
values than patients in the user or control group. This
association might be mediated by a modified conduct in
the consultation and should be considered in further
research.
Since our research question was part of an exploratory
feasibility study investigating potential weaknesses in the
chosen study design, the results regarding the missing
impact of the pathway recommendations (missing var-
iances in monitoring visits, no significance in prescrip-
tion of basic medication) have to be discussed. Reasons
for the found outcome might be up to the intervention
itself (e.g. lacking clarity of the pathway material), the
implementation of the intervention (e.g. lacking aware-
ness of the pathway in daily practice, prescription rou-
tines) or methodological considerations (e.g. choice of
endpoint, no randomization), which is partly in line with
the findings of our qualitative study [29]. Thus, further
feasibility studies should test modifications of the inter-
vention and the study design. In a next step a cluster-
randomized evaluation study according to the MRC-ts.
Kramer et al. Health and Quality of Life Outcomes 2012, 10:78 Page 9 of 10
http://www.hqlo.com/content/10/1/78model [26] should be conducted to assess the effective-
ness of the pathway. Therefore, GPs not familiar with
the pathway should be randomized to an intervention
group receiving a training regarding the pathway and a
control group.
Study limitations
As a result of the not randomized study design, the repre-
sentativeness of the data might be limited. Nevertheless,
due to the similar baseline characteristics of all study
groups – except gender and living with a partner – we as-
sume our results to be valid. We can not exclude a
Hawthorne effect because patients in the intervention
groups might have noticed that they were treated differ-
ently than before and patients in the control group might
have noticed they were treated as usual. Another limita-
tion concerns the different follow-up assessments between
control and intervention groups and the application of the
last observation carried forward method. We thought this
principle to be appropriate since we did not expect re-
markable changes in the control group over time. Due to
practical considerations we included patients with a preva-
lent CHD while incident cases were neglected. This might
have influenced the data. As a consequence of the pre-
analysis we did not include monitoring visits in our multi-
level analysis. To make a global statement how these path-
way recommendations affect patients` HRQoL, reasons
for the missing variance in this variable on practice level
should be investigated in further research.
Conclusions
As our findings show, there were associations between dif-
ferent sociodemographic variables, group membership
and HRQoL but none with pathway related variables like
the recommended basic medication. Thus, further feasibil-
ity studies modifying the intervention and/or the study de-
sign should be conducted to explore the factors hindering
the implementation of the pathway recommendation.
Additionally, as patients in the developer group reported
the highest HRQoL values over time a larger commitment
of the GPs in the developer group can be assumed and
should be considered in further research.
Additional File
Additional file 1: Pocket version of the CHD treatment pathway.
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